Jun 27, 2017
Dr. Ghandehari was awarded a NIH STTR Phase II grant in collaboration with a local company
Congratulations to Dr. Hamid Ghandehari, Professor in the Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, Director of Utah Center for Nanomedicine, Co-Founder and Co-Director of the Nano Institute of Utah and Director of the University of Utah Nanotechnology Training Program for continuing his innovative research.
Dr. Ghandehari was awarded a NIH STTR Phase II grant in collaboration with a local company, TheraTarget, Inc. The project is "In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma". Total costs of the grant are $1,401,869, which ends August 2019.